Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1991 1
1993 1
1994 1
1995 5
1996 2
1997 9
1998 5
1999 6
2000 4
2001 3
2002 1
2003 1
2005 5
2006 1
2007 4
2008 1
2009 2
2010 4
2011 2
2012 4
2013 3
2014 5
2015 4
2016 4
2017 2
2018 6
2019 7
2020 10
2021 5
2022 3
2023 4
2024 5
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

120 results

Results by year

Filters applied: . Clear all
Page 1
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, Pintus E, Sridhar SS, Bambury RM, Emmenegger U, Lindberg H, Morris D, Nolè F, Staffurth J, Redfern C, Sáez MI, Abida W, Daugaard G, Heidenreich A, Krieger L, Sautois B, Loehr A, Despain D, Heyes CA, Watkins SP, Chowdhury S, Ryan CJ, Bryce AH; TRITON3 Investigators. Fizazi K, et al. N Engl J Med. 2023 Feb 23;388(8):719-732. doi: 10.1056/NEJMoa2214676. Epub 2023 Feb 16. N Engl J Med. 2023. PMID: 36795891 Free PMC article. Clinical Trial.
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ; SPARTAN Investigators. Smith MR, et al. N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8. N Engl J Med. 2018. PMID: 29420164 Free article. Clinical Trial.
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14. N Engl J Med. 2019. PMID: 30763142 Clinical Trial.
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B; HERO Study Investigators. Shore ND, et al. N Engl J Med. 2020 Jun 4;382(23):2187-2196. doi: 10.1056/NEJMoa2004325. Epub 2020 May 29. N Engl J Med. 2020. PMID: 32469183 Clinical Trial.
Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.
Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Petrenciuc O, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. N Engl J Med. 2020 Sep 10;383(11):1040-1049. doi: 10.1056/NEJMoa2001342. N Engl J Med. 2020. PMID: 32905676 Clinical Trial.
CPSF3-dependent pre-mRNA processing as a druggable node in AML and Ewing's sarcoma.
Ross NT, Lohmann F, Carbonneau S, Fazal A, Weihofen WA, Gleim S, Salcius M, Sigoillot F, Henault M, Carl SH, Rodríguez-Molina JB, Miller HR, Brittain SM, Murphy J, Zambrowski M, Boynton G, Wang Y, Chen A, Molind GJ, Wilbertz JH, Artus-Revel CG, Jia M, Akinjiyan FA, Turner J, Knehr J, Carbone W, Schuierer S, Reece-Hoyes JS, Xie K, Saran C, Williams ET, Roma G, Spencer M, Jenkins J, George EL, Thomas JR, Michaud G, Schirle M, Tallarico J, Passmore LA, Chao JA, Beckwith REJ. Ross NT, et al. Among authors: carl sh. Nat Chem Biol. 2020 Jan;16(1):50-59. doi: 10.1038/s41589-019-0424-1. Epub 2019 Dec 9. Nat Chem Biol. 2020. PMID: 31819276 Free PMC article.
Complement activation profiles in patients with immune checkpoint inhibitor-associated neuromuscular immune-related adverse events.
Müller-Jensen L, Möhn N, Skripuletz T, Carl S, Thomas J, Grote-Levi L, Nay S, Ivanyi P, von Wasielewski I, Gutzmer R, Dittmayer C, Stenzel W, Knauss S, Endres M, Lünemann JD, Boehmerle W, Huehnchen P. Müller-Jensen L, et al. Among authors: carl s. J Neurol. 2025 Jun 12;272(7):459. doi: 10.1007/s00415-025-13181-2. J Neurol. 2025. PMID: 40506552 Free PMC article.
Discovery and Characterization of a First-in-Class LIV1-TLR7/8 Immunomodulatory Conjugate with Robust Myeloid Activation and Antitumor Activity.
Yamazoe S, Poudel Y, Sega E, Mukhopadhyay A, Ramakrishnan R, Ukairo O, Liu S, Akter R, Sadanala K, Que K, Cheng Q, Kotapati S, Deshpande M, Cox M, Chourey S, Gupta A, Kempson J, Pabbisetty K, Kaspady M, Bhattasali D, Yip S, Wu DR, Pookot D, Li Y, Kozhich A, Drexler D, Carl S, Deyanova E, Smith M, Chan H, West S, Diong SJ, Chang A, Florin L, Mathur A, Strop P, Zapf CW, Law D, Wilson N, Broz M, Chekler EP. Yamazoe S, et al. Among authors: carl s. J Med Chem. 2025 Jun 12;68(11):11322-11339. doi: 10.1021/acs.jmedchem.5c00264. Epub 2025 May 24. J Med Chem. 2025. PMID: 40411528 Free PMC article.
120 results